Tag: care

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- GROWNSY, a baby care innovator trusted by more than 3 million households worldwide, today announced its full Amazon Prime Day 2026 strategy under the campaign theme "Baby Grows. Feeding Grows." This year's Prime Day, confirmed by Amazon as a June event across 26 countries including the United States, United Kingdom, Canada, Germany, France, Italy, and Spain, represents the earliest and most significant mid-year shopping window in the platform's history. GROWNSY is treating it as exactly that: not a routine promotion, but a pivotal moment to meet parents where they are.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

New York health technology company combines general wellness, mental health, and nutrition AI into a single personalized ecosystem - and prepares its Vital IQ™ wearable for market